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Epidemic typhus is a rickettsial disease that is contracted via ticks and lice found on the flying 
squirrel. The disease is caused by Rickettsia prowazekii, an intracellular, gram-negative 
coccobacillus. The biosynthetic pathways of Rickettsia prowazekii and its host are intertwined. 
Therefore, the ideal antipathogenic drugs would not target a protein that is found within the 
biochemical pathway of the human host. There is a type II fatty acid synthase pathway that is 
unique to Rickettsia prowazekii, which can be distinguished from the multienzyme type I fatty-
acid synthase pathway used in humans. Fab G 3-ketoacyl-(acyl-carrier-protein) reductase 
(RpFabG) is a protein that is specific to this type II pathway. Hence, this research is focused on 
finding a small molecule drug that inhibits RpFabG. The coding DNA sequence for the RpFabG 
protein was previously cloned into a pNIC-Bsa4 plasmid, which was transformed into 
BL21(DE3) Escherichia coli and Dh5α competent cells. The transformed bacteria were cultured 
in LB media, and the cells were harvested. The expressed protein was purified via Ni-NTA 
affinity chromatography, made possible by a His6 tag on the vector. Gel electrophoresis was 
performed to determine the purity of the obtained protein sample; due to indication of slight 
contamination, gel filtration fast protein liquid chromatography was run on a concentrated 
protein sample. Genetic Optimization of Ligand Docking (GOLD) is a molecular docking 
software package that was used to rank potential inhibitors of RpFabG according to binding 
strength; ethyl acetoacetate (EAA) and acetoacyl coenzyme A (AAC) were determined to have 
high binding strengths and thus determined to be strong potential inhibitors. An enzyme assay 
was run to determine the functionality of the enzyme, with EAA and AAC as substrates. AAC 
successfully decreased the enzymatic activity of RpFabG, suggesting its potential as a novel drug. 
DSF assay results were equivocal, indicating that inhibition assays should be run on AAC to 




Proteins play a central role in disease processes. By targeting and inhibiting protein function 
within a cell, it is possible to mitigate the deleterious outcomes of disease states in humans. The 
most effective indicator of an inhibitor’s potency is its performance in in vitro or in vivo wet lab 
assays. However, such assays are expensive and time consuming to perform. Progressing a drug 
though initial binding assays, animal models and eventual human clinical trials can take 10-15 
years and upwards of 800 million dollars. The Virtual Cures stream streamlines the 
aforementioned process by virtually analyzing the structural and chemical bonding relationships 
between hundreds of potential inhibitors and the protein target. Inhibitors with low binding 
scores can be screened out, and inhibitors with high scores can be purchased and then tested in 





Epidemic typhus is a rickettsial disease that results in the death of 10-60 percent of all patients 
who contract it. Typhus is most prevalent in cold, unhygienic geographical regions [3]. Common 
symptoms of typhus include but are not limited to delirium, dry cough, high fever, aching of the 
joints and muscles, decreased blood pressure, and rashes. Humans contract typhus via ticks and 
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lice that are found on the flying squirrel. The disease is caused by Rickettsia prowazekii, an 
intracellular, gram-negative coccobacillus. Rickettsia prowazekii is the only member of the 
genus Rickettsia to cause a latent infection, which can manifest years to decades later. This 
milder recurrence of the disease is known as Brill-Zinsser disease [7]. The relatively high fatality 
rate of patients who contract typhus makes finding a potential inhibitor of Rickettsia prowazekii 
advantageous. 
 
Rickettsia prowazekii relies heavily on its host to carry out its biosynthetic activities, because it 
has a limited genome [6]. Therefore, the biosynthetic pathways of Rickettsia prowazekii and its 
host are intertwined. The ideal antipathogenic drugs would not target a protein that is found 
within the biochemical pathway of the human host. Rickettsia prowazekii utilizes a unique 
biochemical pathway for the biosynthesis of fatty acids; the type II fatty acid synthase pathway. 
The end products of this pathway are the elongated fatty acids that are used to construct the lipid 
bilayer. Without this enzyme the cell wall would be compromised, leading to cell death. This 
biochemical pathway can be distinguished from the human biosynthesis of the lipid bilayer, 
which relies on a multienzyme type I fatty-acid synthase – a large peptide in humans that serves 
multiple biochemical purposes. The fatty acids are synthesized within the different domains of 
the peptide.  
 
3-Ketoacyl-(acyl-carrier-protein) [3-ketoacyl-(ACP)] reductase, more commonly known as 
RpFabG, is specific to the type II pathway found in Rickettsia prowazekii. More specifically, it is 
the third enzyme that catalyzes the necessary chemical reaction [4]. Because of it’s potential for 
use as a bioterrorist, Fab G 3-ketoacyl-(acyl-carrier-protein) reductase is placed in the second 
highest pathogen biodefense category as delineated by the National Institute of Allergy and 
Infectious Diseases. There is no known homolog of RpFabG in humans. A BLAST search 
revealed the highest homology to have a 93% query cover, with a 38% identity match – a 
relatively low percentage [1].  
 
Enzyme Name 3-oxoacyl-[acyl-carrier-protein] reductase 
Enzyme Number 1.1.1.100 
Isoelectric Point (pI) 9.07 
Molecular Weight 25.9 kD 
Molar Extinction Coefficient 10,680 M-1cm- 
Substrate (3R)-3-hydroxyacyl-[acyl-carrier protein] 
Cofactor NADPH 
 
Table 1: Table displaying characteristics of 3-ketoacyl-(acyl-carrier-protein) reductase, more 
commonly known as FabG, as well as the substrates and cofactors involved in the reaction 
mechanism associated with FabG [4]. 
 
 4 
Figure 1: Reaction mechanism involving 3-ketoacyl-(acyl-carrier-protein) reductase. The 
substrate in this reaction is (3R)-3-hydroxyacyl-[acyl-carrier protein], while the cofactor in this 
reaction is NADPH [4]. 
 
Current available antibiotics for typhus include Doxycycline, Tetracycline, and Chloramphenicol 
[3]. However, there aren’t any known, or commercially available inhibitors specifically for 3-
ketoacyl-(acyl-carrier-protein) reductase. There are however known inhibitors for homologs of 
the protein that differ slightly in structure from RpFabG. Flavonoids have been discovered as an 
efficient inhibitor in Plasmodium falciparum and Escherichia coli; there is experimental 
evidence that the flavonoids inhibit the synthesis of fatty acids in the organism. T butein, 
isoliquirtigenin, 2,29,49-trihydroxychalcone and fisetin, are four flavonoids that have been 
determined as inhibitors of  β-hydroxyacyl-ACP dehydratase in Mycobacterium bovis. However 
elevated Rv0636 concentrations dampen the effect of these flavonoids as inhibitors [2]. 
Figure 2: Chemical structure of T butein, isoliquirtigenin, 2,29,49-trihydroxychalcone, and 
fisetin 
 
2. MATERIALS & METHODS  
 
2.1 Chemical Reagents   
 
All reagents were purchased from Sigma-Aldrich (St. Louis, MO), unless otherwise specified. 
Black 384-well polypropylene plates (catalog no. 264576) were from Nalge Nunc (Rochester, 
NY). Microcentrifuge tubes of 1.5 mL and 50mL were purchased from Fisher Scientific 
(Pittsburgh, PA). A custom HEPES buffer was created to minimize protein precipitation. This 
custom HEPES buffer solution was prepared with 20 mM HEPES (pH 7.5), 500 mM NaCl, and 
5% glycerol. The protein was maintained in this buffer throughout the experimental protocol.  
 
2.2 Virtual Screening 
 
Virtual Screening is a computational method that scans libraries of compounds and determines 
which structures are most likely to bind to the active site of a target; these structures can then be 
used in in vitro assays.  There are two main types of virtual screening – structure based, and 
ligand based. Ligand based screening integrates the pharmacophoric features of multiple ligands 
to extract common chemical features essential for substrate binding. This information is then 
used to screen potential compounds. Structure based screening employs docking algorithms and 
scoring functions to estimate the binding affinity of a substrate to the active site of a target of 
interest.  
 
Structure based screening was used to screen potential novel inhibitors of 3-ketoacyl-(acyl-
carrier-protein) reductase (RpFabG) in Rickettsia prowazekii. Specifically, high throughput 
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molecular docking software (GOLD) was used to screen a commercial library of ligands 
(Chembridge Diversity Set) against the acetoacetyl-ACP region of the active site (PDB ID 
3OP4). Water was removed and hydrogen was added to the virtual structure before docking. A 
Ti3D Drug Discovery high performance computer (DDFE) consisting of 64 parallel cores was 
used to run screening jobs. Each compounds was assigned a fitness score indicative of substrate 
binding strength. The ligands with the best GOLD scores were selected and tested in vitro.  
 
Although a 3-dimensional crystal structure is present for 3-ketoacyl-(acyl-carrier-protein) 
reductase [PDB 3F9I], the available structure has not been crystallized with a natural substrate. 
Crystallization of a protein with a natural substrate aids in the identification of the active site. 
The software used to develop a 3-dimensional model of the protein, PyMOL, uses a naturally 
bound substrate to identify the initial active site. For this reason, a homologous protein [PDB 





Figure 3: 3-ketoacyl-(acyl-carrier-protein) reductase from Vibrio cholerae O1 biovar eltor str. 
N16961 in complex with NADP+; PDB ID (3OP4). 
 
2.3 Gene Construction via PCR  
 
The gene of interest was inserted via ligation independent cloning into the pNIC-Bsa4 vector. 
Complimentary cohesive ends were generated for the gene of interest and pNIC-Bsa4 vector via 
T4 DNA polymerase. Following annealing of the vector and gene of interest, the plasmid was 
transformed into BL21(DE3) Escherichia coli as well as Dh5α. BL21(DE3) cells are expression 
hosts, and therefore possess the cellular machinery required for expression. Dh5α is a cloning 
host, and allows isolate on of the plasmid without degradation. The plasmid contained a T7 
promoter, which is inducible by Isopropyl β-D-1-thiogalactopyranoside (IPTG) and activates 
gene expression. The vector also contained a His6 tag, which enabled purification via Ni-NTA 
affinity chromatography. Additionally, the vector contains a kanamyacin resistance gene, which 
allowed bacterium containing the gene of interest to be isolated.  
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2.4 RpFabG Protein Expression and Purification 
 
The transformed cells were cultured overnight in Luria broth (LB) media at 37oC. Kanamyacin 
was added to ensure that only bacteria containing the gene of interest were isolated. Isopropyl β-
D-1-thiogalactopyranoside (IPTG) was added at an OD600 absorbance of 0.5, which was 
measured using a Vernier Visible Spectrophotometer. This ensured that the IPTG is added when 
the bacteria are in log phase, optimizing protein yield. The bacteria were harvested via 
centrifugation using a JA10 rotor and Beckman Centrifuge. The obtained pellet was resuspended 
in the custom HEPES buffer and then lysed via sonication to release the protein. The protein was 
then purified using Ni-NTA affinity chromatography. The His6 tag allows binding of the protein 
to the Ni-NTA resin. A Wash buffer with a low concentration of imidazole was run through the 
chromatography column to displace extraneous proteins that didn’t contain the His6 tag, and 
were therefore bound less tightly to the resin. An elution buffer with a high concentration of 
imidazole was then run through the column. The high concentration of imidazole eluted the 
protein of interest by competing with the protein for binding sites to the resin. The eluted 
samples were run through a 0.45µM PES syringe to remove large particulate matter. Protein 
concentration was determined by UV-VIS spectrophotometry at a wavelength of 250nm. Once 
the protein was obtained, it was concentrated; half the sample was stored in glycerol stored at 
4°C, while the other half was snap frozen using liquid nitrogen and stored at -80°C.  
 
2.5 Spectrophotometric Enzyme Assay 
 
Inhibitor efficacy was assessed in vitro via a spectrophotometric enzyme assay. NADPH and the 
two ligands with the highest GOLD scores – acetoacyl Coenzyme A, and ethylacetoacetate – 
were used as substrates for the enzymatic assay of RpFabG. The rate of NADPH oxidation was 
obtained by measuring the decrease in absorbance of NADPH at 30°C and a wavelength of 
420nm using a Vernier Visible Spectrophotometer. Assays were performed with 0.2 to 0.6 µg 
RpFabG in a custom HEPES buffer in a final volume of 80µl. Samples were sealed in a 





The coding DNA sequence for the gene of interest, which had already been cloned into pNIC-
Bsa4, was transformed into BL21(DE3) Escherichia coli as well as Dh5α. The transformed 
bacteria were then plated on kanamyacin agar plates to isolate the bacteria containing the 
plasmid. The bacteria were plated at two different concentrations – 10µL and 50 µL – with the 
latter yielding more bacterial colonies. Protein expression yielded a concentration of 
3.465mg/mL, indicating a sufficient concentration to proceed with characterization.  
 
Gel electrophoresis was performed and produced the gel in Figure 4. The first five samples 
should not produce a visible band at the molecular weight of RpFabG, since there should be little 
to no protein in these samples. A distinct band should only be visible for samples six through 
nine, since these are the samples for elution 1 and 2. Elution 1, in lanes 6 and 8, produced a 
distinct band corresponding to the molecular weight of RpFabG (25.9 kD). There is slight 
contamination surrounding the band, indicating that additional purification protocols such as 
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FPLC are necessary. Elution 2, in lanes 7 and 9, also produced a distinct band with significantly 
less contamination. Purification of the protein produced a protein concentration of 3.285mg/mL 
in elution 1, and 0.365mg/mL in elution 2. A protein concentration above 1mg/mL is generally 
sufficient to proceed with enzyme assays. However, evidence of slight protein contamination 
indicated further purification protocols. Fast protein liquid chromatography (FPLC) was 
performed on a combined sample of elution 1 and 2. The protein exists as both a monomer and a 
dimer, as shown in Figure 5. Both samples were collected, and the active dimerized form was 
used in spectrophotometric enzyme assays. 
 
  
Figure 4: SDS-PAGE gel characterizing RpFabG purified by Ni-NTA. Lane 1 contains the 
ladder (11-245 kDa). Lane 6 & 8 contains Elution 1 (250 mM Imidazole) and Lane 7 & 9 





Figure 5: SEC-FPLC graph for RpFabG run on an S200 column. The first peak at 40mL 
corresponds to the dimerized form of the protein, while the latter corresponds to the monomeric 
form at 82mL. 
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The enzymatic activity of RpFabG was measured with acetoacyl coenzyme A (AAC) and 
ethylacetoacetate (EAA) as the substrate, in the presence of NADPH. A spectrophotometric 
assay was used to measure the decrease in absorbance of NADPH, and thus the efficacy of the 
inhibitor. Figure 6, which corresponds to the enzyme assay performed with acetoacyl coenzyme 
A, shows a decrease in absorbance at 340nm. This decrease in absorbance indicates that NADPH 
is being oxidized by RpFabG to NADP+ and that the enzyme of interest, RpFabG, is active. 
Additionally, this decrease in absorbance suggests that the affinity of RpFabG for NADPH is 
therefore comparable both with and without the presence of AAC. Figure 7, which corresponds 
to the enzyme assay performed with ethylacetoacetate (EAA), does not show a decrease in 
absorbance at 340nm. The lack of a decrease in absorbance indicates that NADPH is not being 


















4.1 Optimizing Protein Yield  
 
The experimental protocol was adjusted several times in order to optimize protein yield. In order 
to optimize protein expression, the culture had to reach an OD600 absorbance of 0.5 prior to 
induction. Across multiple rounds of expression, the culture was induced just under an OD500 of 
0.5. If induced too quickly, the bacteria may not be in log phase, and may not be reproducing 
rapidly enough. Therefore in future trials, induction at an OD500 of 0.5 may produce higher 
protein yield. However, the obtained concentration of expressed protein wasn’t a significant 
impediment to further protocols.   
 
Furthermore, the harvested protein tended to precipitate out of solution throughout the 
expression and purification process. This precipitated protein was not functional, and could not 
be used in enzyme assays. Given that the protein of interest was stored in solution for several 
days between expression and subsequent purification protocols, measures were taken to 
minimize protein precipitation. It has been reported that a 0.5 mM solution in 0.02 M NaOH(pH 
12.3) showed no loss of RpFabG purity in a week at 4 °C or - 85 °C, but a 13% loss at –20 °C. 
Storage at –20 °C resulted in decomposition of the compound to produce b-NADP and 
monophosphoadenosine 5-diphosphoribose, even when the protein was protected from light [4]. 
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Therefore, once the protein was concentrated, half the sample was stored in glycerol stored at 
4°C, while the other half was snap frozen using liquid nitrogen and stored at -80°C. Additionally, 
the protein was stored in a custom HEPES buffer prepared with 20 mM HEPES (pH 7.5), 500 
mM NaCl, and 5% glycerol to minimize precipitation. Overall, the experimental protocol was 
successfully modified to yield a high enough protein concentration to proceed with enzyme 
assays. However, a significant amount of time was devoted to repeated trials in order to develop 
this modified protocol.  
 
4.2	  Future	  Directions	  	  
 
Preliminary in vitro assays indicate EAA as a potential inhibitor of RpFabG. The next step would 
be to run a Michaelis Menten assay and calculate kinetic coefficients to determine if EAA is a 
competitive inhibitor of RpFabG. This kinetic analysis of RpFabG may be performed with 
various concentrations of NADPH in the presence of constant concentrations of EAA. A similar 
kinetic analysis can be performed with various concentrations of EAA in the presence of 
constant concentrations of NADPH. 
 
A Differential Scanning Fluorimetry (DSF) binding assays may be performed on RpFabG to 
assess protein functionality prior to running enzyme assays. DSF assays may also be used to test 
inhibitor efficacy, as successful ligand binding would be indicated by the increased thermal 
stability of a protein. If DSF assays provide clarification as to EAA’s potential as an inhibitor of 
RpFabG, the next step would be to run inhibition assays with RpFabG and EAA. In an inhibition 
assay, RpFabG will be incubated at room temperature with the determined inhibitor to yield 
IC50 values, which will provide a measure of inhibitor efficacy.  
 
Overall, this initial work is a good starting point to continue testing potential novel inhibitors of 
RpFabG. Site directed mutagenesis could be performed in order to pinpoint chemical properties 
required for a compound to successfully inhibit RpFabG. Furthermore, additional rounds of 
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